Hot topics in urological health economics. A mini review

Archivio Italiano di Urologia e Andrologia

Volumn 84, Issue 2, 2012, Pages 47-52

  Racioppi, Marco ^a   Palermo, Giuseppe ^a   D'Addessi, Alessandro ^a   Pinto, Francesco ^a   Sacco, Emilio ^a   D'Agostino, Daniele ^a   Vittori, Matteo ^a   Bassi, Pier Francesco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Economic burden; Health economics; Urologic cancer costs; Urology

Indexed keywords

BLADDER CANCER; CYSTECTOMY; EXTRACORPOREAL LITHOTRIPSY; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; PERCUTANEOUS NEPHROLITHOTOMY; PROSTATE CANCER; REVIEW; UROLITHIASIS; UROLOGY;

HEALTH CARE COSTS; HUMANS; UROLOGIC DISEASES;

EID: 84865177281     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Li C, Ekwueme DU, Rim SH, Tangka FK. Years of potential life lost and productivity losses from male urogenital cancer deaths - United States, 2004. Urology 2010; 76:528-35.
2. Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995. Urology 1998; 51:355-361. (Pubitemid 28136669)
3. Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: a review of current methods. Pharmacoeconomics 2006; 24:869-890. (Pubitemid 44338298)
4. Hu TW, Wagner TH. Economic considerations in overactive bladder. Am J Manag Care 2000; 6(11 Suppl):S591-S598. (Pubitemid 30649380)
5. Erdem N, Chu FM. Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med 2006; 119(3 Suppl 1):29-36.
6. Wagg AS, Cardozo L, Chapple C, et al. Overactive bladder syndrome in older people. BJU Int 2007; 99:502-509. (Pubitemid 46238818)
7. Wu EQ, Birnbaum H, Marynchenko M, et al. Employees with overactive bladder: work loss burden. J Occup Environ Med 2005; 47:439-446. (Pubitemid 40656777)
8. Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006; 68(2 Suppl):3-8. (Pubitemid 44189491)
9. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6S574-S579.
10. Stark JR, Perner S, Stampfer MJ, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009; 27:3459-3464.
11. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97:1248-1253. (Pubitemid 41535365)
12. Riley GF, Potosky AL, Lubits JD, et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33:828-41.
13. Baker S, Kessler LG, Smucker RC. Site-specific treatment costs for cancer: an analysis of the Medicare continuous history sample file. In Scheffler RM, Andrews NC (editors) Cancer care and costs: DRG's and beyond 1989. Ann Arbor (MI): Health administration Press perspectives, 1989.
14. Becerra Bachino V, Cots F, Guedea F, et al. Cost comparison of three treatments for localized prostate cancer in Spain:. radical prostatectomy, prostate brachytherapy and external 3D conformal radiotherapy. Gac Sanit 2011; 25:35-43.
15. Jayadevappa R, Schwartz JS, Chhatre S, et al. The burden of out-of-pocket and indirect costs of prostate cancer. Prostate 2010; 70:1255-64.
16. Snyder CF, Frick KD, Blackford AL, et al. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer 2010; 116:5391-9.
17. Labrie J, van der Graaf Y, Buskens E, et al. Protocol for Physiotherapy Or TVT Randomised Efficacy Trial (PORTRET): a multicentre randomised controlled trial to assess the cost-effectiveness of the tension free vaginal tape versus pelvic floor muscle training in women with symptomatic moderate to severe stress urinary incontinence. BMC Womens Health 2009; 9:24.
18. Subak LL, Brown ]S, Kraus SR, et al. Diagnostic Aspects of Incontinence Study Group. The "costs" of urinary incontinence for women. Obstetrics & Gynaecology 2006; 107:908-16.
19. Kinchen KS, Long S, Orsini L, Crown W, Swindle R. A retrospective claims analysis of the direct costs of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:403-11. (Pubitemid 38072492)
20. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61:37-49. (Pubitemid 36151708)
21. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20:327-336. (Pubitemid 44175300)
22. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003; 61:1123-1128. (Pubitemid 36693985)
23. Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6(11 suppl):S580-S590. (Pubitemid 30649379)
24. Schlenk EA, Erlen JA, Dunbar-Jacob J, et al. Healthrelated quality of life in chronic disorders: a comparison across studies using the MOS SF-36. Qual Life Res 1998; 7:57-65. (Pubitemid 28113965)
25. Hu TW, Moore K, Subak L, et al. Economics of incontinence, in Abrams P, Cardozo L, Khoury S, et al (eds), Incontinence. Plymouth, Health Publication Ltd, 2002; 965-983.
26. Wu EQ, Birnbaum H, Marynchenko M, et al. Employees with overactive bladder: work loss burden. J Occup Environ Med 2005; 47:439-46. (Pubitemid 40656777)
27. Brown ML, Fintor L. The economic burden of cancer. In: Greenwald P, Kramer BS, Weed DL, Editors, Cancer Prevention and Control, Marcel-Dekker, New York 1995; 69-81.
28. Friedman SM. The inflation calculator (2000) Available at: http./www.westeggcom/inflation/. Accessed April 22, 2005.
29. Svatek R, Sagalowsky A, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis Urol Oncol 2006; 24:338-343. (Pubitemid 43963410)
30. Malkowicz SB. Management of superficial bladder cancer. In: Walsh PC, Retik AB, Vaughan ED Jr. et al. (eds), Campbell's Urology (8th ed.), W.B. Saunders, Philadelphia 2002; 2785-2802.
31. Raghavan D, Shipley WU, Garnick MB, et al. Biology and management of bladder cancer, N Engl J Med 322 1990; 322:1129-1138.
32. Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 1999; 161:62-65. (Pubitemid 29422291)
33. Mark Hong Y, Loughlina KR. Economic Impact of Tumor Markers in Bladder Cancer Surveillance. Urology 2008; 71:131-135.
34. Racioppi M, Volpe A, Falabella R, et al. The cost of treatment and follow-up of bladder cancer in Italy. Arch Ital Urol Androl 2007; 79:111-7. (Pubitemid 350073481)
35. Kilbridge KL, Kantoff PW, Loughlin KR, et al. Is bacillus calmetteguerin(BCG) im,munotherapy cost-effective in recurrent high grade transitional cell cancer(TCC)?(abstract). J Urol 1997; 157(4 Suppl.):214.
36. Engel RP, Witjes JA. Perioperative instillation therapy in superficial bladder cancer: is it effective regarding outcome and costs? Curr Opin Urol 2009; 19:511-5.
37. Feifer A, Xie X, Brophy JM, et al. Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system. Urology 2010; 76:652-6.
38. Kulkarni GS, Alibhai SM, Finelli A, et al. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer 2009; 115:5450-9.
39. Lotan Y. Economics of robotics in urology. Curr Opin Urol 2010; 20:92-7.
40. Lotan Y, Pearle MS. Economics of stone management. Urol Clin North Am 2007; 34:443.
41. Pearle MS, Calhoun EA, Curhan GC. Urologic Diseases in America Project: urolithiasis. J Urol 2005; 173:848.
42. Curhan GC. Epidemiology of stone disease. Urol Clin North Am 2007; 34:287.
43. Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: A replication and update. Health Care Financ Rev 1985; 7:61-80. (Pubitemid 17008319)
44. Ljunghall S. Incidence of upper urinary tract stones. Mineral Electrolyte Metab 1987; 13:220-227. (Pubitemid 17149573)
45. Saigal CS, Joyce G, Timilsina AR. Direct and indirect costs of nephrolithiasis in an employed population: Opportunity for disease management? Kidney International 2005; 68:1808-1814. (Pubitemid 43169926)
46. Hyams ES, Shah O. Percutaneous nephrostolithotomy versus flexible ureteroscopy/holmium laser lithotripsy: cost and outcome analysis. J Urol 2009; 182(3):1012-7.